AstraZeneca

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Employees: 89.9K

Market Cap: $270.3B

Website: http://www.astrazeneca.co.uk

Introduction: AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Clinical Trials

Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877

Phase 1

Terminated

Conditions: Lymphoma
NHL
Non-Hodgkin Lymphoma

First Posted Date: 2007-05-09

Last Posted Date: 2009-09-24

Lead Sponsor: AstraZeneca

Target Recruit Count: 44

Registration Number: NCT00471367

Locations: 🇺🇸
Research Site, Greenville, South Carolina, United States

Phase 3/Safety & Efficacy of Esomeprazole in Infants

Phase 3

Completed

Conditions: Gastroesophageal Reflux Disease (GERD)

Interventions: Drug: Open Label Run In Esomeprazole
Drug: Double Blind Esomeprazole
Drug: Double Blind Placebo

First Posted Date: 2007-05-02

Last Posted Date: 2014-06-02

Lead Sponsor: AstraZeneca

Target Recruit Count: 98

Registration Number: NCT00468559

Locations: 🇵🇱
Research Site, Wroclaw, Poland

A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes

Phase 4

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: rapid acting insulin (Humalog® [insulin lispro], Novolog® [insulin aspart], or Apidra® [insulin glulisine])
Drug: pramlintide acetate (Symlin)
Drug: basal insulin (Lantus® [insulin glargine], or Levemir® [insulin detemir])

First Posted Date: 2007-05-01

Last Posted Date: 2015-04-14

Lead Sponsor: AstraZeneca

Target Recruit Count: 112

Registration Number: NCT00467649

Locations: 🇺🇸
Research Site, Spokane, Washington, United States

Local Phase 4 Pan-European SMART Study

Phase 4

Completed

Conditions: Asthma

First Posted Date: 2007-04-20

Last Posted Date: 2010-03-22

Lead Sponsor: AstraZeneca

Target Recruit Count: 8424

Registration Number: NCT00463866

Locations: 🇬🇧
Research Site, Yaxley, United Kingdom

AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies

Phase 1

Active, not recruiting

Conditions: Tumor
Cancer

Interventions: Drug: AZD6244

First Posted Date: 2007-04-20

Last Posted Date: 2024-11-22

Lead Sponsor: AstraZeneca

Target Recruit Count: 58

Registration Number: NCT00463814

Locations: 🇬🇧
Research Site, Sutton, United Kingdom

A Multicenter Study Comparing the Safety and Efficacy of ABT-335 and Rosuvastatin Calcium Combination Therapy to Monotherapy in Subjects With Dyslipidemia

Phase 3

Completed

Conditions: Hypercholesterolemia
Dyslipidemia

Interventions: Drug: ABT-335
Drug: rosuvastatin calcium
Drug: ABT-335 and rosuvastatin calcium

First Posted Date: 2007-04-20

Last Posted Date: 2012-10-03

Lead Sponsor: AstraZeneca

Target Recruit Count: 760

Registration Number: NCT00463606

Locations: 🇺🇸
Site Reference ID/Investigator# 4387, Philadelphia, Pennsylvania, United States
🇺🇸
Site Reference ID/Investigator# 5585, Chicago, Illinois, United States
🇺🇸
Site Reference ID/Investigator# 4483, Gilbert, Arizona, United States

and more 165 locations

Phase I, Open-label, Dose Escalation of AZD4877 in Hematologic Malignancies

Phase 1

Terminated

Conditions: Lymphoma

First Posted Date: 2007-04-16

Last Posted Date: 2011-01-25

Lead Sponsor: AstraZeneca

Target Recruit Count: 75

Registration Number: NCT00460460

Locations: 🇺🇸
Research site, Buffalo, New York, United States
🇨🇦
Research Site, Toronto, Ontario, Canada

Rapid Versus Conventional Titration of Quetiapine in Schizophrenia/Schizoaffective Disorder

Phase 3

Terminated

Conditions: Psychotic Disorders
Schizophrenia
Schizoaffective Disorders

First Posted Date: 2007-04-09

Last Posted Date: 2007-11-27

Lead Sponsor: AstraZeneca

Target Recruit Count: 234

Registration Number: NCT00457899

Locations: 🇬🇧
Research Site, Warrington, United Kingdom

AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.

Phase 2

Completed

Conditions: Advanced Breast Cancer

Interventions: Drug: AZD2171
Drug: Fulvestrant

First Posted Date: 2007-04-02

Last Posted Date: 2016-08-03

Lead Sponsor: AstraZeneca

Target Recruit Count: 75

Registration Number: NCT00454805

Locations: 🇧🇷
Research Site, São Paulo, Brazil

AZD8330 First Time in Man in Patients With Advanced Malignancies

Phase 1

Completed

Conditions: Cancer

First Posted Date: 2007-03-29

Last Posted Date: 2011-08-24

Lead Sponsor: AstraZeneca

Target Recruit Count: 83

Registration Number: NCT00454090

Locations: 🇳🇴
Research Site, Oslo, Norway

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy